Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8007380 | 1.00 | ANPEP (0.52) | ANPEPERAP1ERAP2ACESMN1; SMN2 | |
| SCHEMBL1029067 | 1.00 | ANPEP (0.52) | ANPEPERAP1ERAP2ACESMN1; SMN2 | |
| SCHEMBL8896138 | 0.88 | GRIK1 (0.50) | ANPEPERAP1ERAP2HTR2AGRIK1 | |
| SCHEMBL13629461 | 0.88 | GRIK1 (0.50) | ANPEPERAP1ERAP2HTR2AGRIK1 | |
| SCHEMBL8895432 | 0.88 | GRIK1 (0.50) | ANPEPERAP1ERAP2HTR2AGRIK1 | |
| SCHEMBL27527666 | 0.86 | S1PR2 (0.50) | ANPEPERAP1ERAP2GRIK1 | |
| SCHEMBL16234919 | 0.80 | TAAR1 (0.47) | TAAR1HTT | |
| SCHEMBL28898297 | 0.80 | ANPEP (0.33) | ANPEPERAP1ERAP2ACE | |
| SCHEMBL10068447 | 0.80 | ESR1 (0.48) | ANPEPERAP1ERAP2TAAR1ALDH1A1 | |
| SCHEMBL7266310 | 0.78 | ACE (0.47) | ANPEPERAP1ERAP2ACESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451209-A4 | TETRA-,PENTA-,HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LAB (US) | 2009-06-03 | — | — | EP | claimed |
| EP-1078002-B1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LAB (US) | 2008-05-21 | — | — | EP | claimed |
| US-20080071062-A1 | TETRA-, PENTA-, HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | HAVIV FORTUNA | 2008-03-20 | — | — | US | claimed |
| EP-1461356-A4 | HEXA-, HEPTA-, AND OCTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LAB (US) | 2007-12-12 | — | — | EP | claimed |
| US-20070167376-A1 | Hexa-, Hepta-, and Octapeptides Having Antiangiogenic Activity | HAVIV FORTUNA | 2007-07-19 | — | — | US | claimed |
| US-7169888-B2 | Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2007-01-30 | — | — | US | claimed |
| US-7122625-B2 | Hexa-, hepta-, and octapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-10-17 | — | — | US | claimed |
| US-20060194737-A1 | Hepta-, octa-and nonapeptides having antiangiogenic activity | HAVIV FORTUNA | 2006-08-31 | — | — | US | claimed |
| US-7067490-B2 | Hepta-, Octa-and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-06-27 | — | — | US | claimed |
| US-20050124548-A1 | Peptide antiangiogenic drugs | HENKIN JACK (US) | 2005-06-09 | — | — | US | claimed |
| US-20030105022-A1 | Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-06-05 | — | — | US | claimed |
| US-20030096758-A1 | HEPTA-, OCTA- and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-05-22 | — | — | US | claimed |
| WO-2003037268-A2 | HEPTA-, OCTA- AND NONAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-05-08 | — | — | WO | claimed |
| WO-2003037266-A2 | TETRA-, PENTA-, HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-05-08 | — | — | WO | claimed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | claimed |
| EP-1232183-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2002-08-21 | — | — | EP | claimed |
| WO-2001038397-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001038347-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| EP-1078002-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999061476-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124548-A1 | Peptide antiangiogenic drugs | VEGFA, NPPA, FLT1 | ANPEP 50/4885ERAP1 562/4885ERAP2 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.